Medical Manuscript: Serum Total Testosterone as a Prognostic Indicator in Male Patients With Terminal Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Won | - |
dc.contributor.author | Hwang, In Cheol | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Kyung, Sun Young | - |
dc.contributor.author | Ahn, Hong Yup | - |
dc.date.available | 2020-02-28T01:44:45Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 1049-9091 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8232 | - |
dc.description.abstract | The role of total serum testosterone in the prognosis of terminal cancer is unclear. We retrospectively investigated the total serum testosterone level in 69 male patients with terminal cancer in a palliative care unit. The association between the serum testosterone level and survival was assessed using Cox proportional hazard model. The median value of serum total testosterone was 44.5 ng/dL, far lower than previously reported in patients with advanced cancer. Multivariate analysis revealed thrombocytopenia (adjusted hazard ratio [aHR], 2.68), hypoalbuminemia (aHR, 2.02), azotemia (aHR, 2.67), and lower serum testosterone level (aHR, 2.03) were significantly negatively prognostic of survival. Lower serum testosterone level was an independent unfavorable prognostic factor for life expectancy in male patients with terminal cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE | - |
dc.subject | ANDROGEN DEFICIENCY | - |
dc.subject | SURVIVAL PREDICTION | - |
dc.subject | SYMPTOM BURDEN | - |
dc.subject | HYPOGONADISM | - |
dc.subject | MEN | - |
dc.subject | CACHEXIA | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | ASSOCIATION | - |
dc.subject | MORTALITY | - |
dc.subject | CARCINOMA | - |
dc.title | Medical Manuscript: Serum Total Testosterone as a Prognostic Indicator in Male Patients With Terminal Cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000375837200011 | - |
dc.identifier.doi | 10.1177/1049909115574492 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, v.33, no.5, pp.483 - 488 | - |
dc.identifier.scopusid | 2-s2.0-84964941495 | - |
dc.citation.endPage | 488 | - |
dc.citation.startPage | 483 | - |
dc.citation.title | AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE | - |
dc.citation.volume | 33 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Kim, Se Won | - |
dc.contributor.affiliatedAuthor | Hwang, In Cheol | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Kyung, Sun Young | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | palliative care | - |
dc.subject.keywordAuthor | prognostication | - |
dc.subject.keywordAuthor | serum testosterone | - |
dc.subject.keywordPlus | ANDROGEN DEFICIENCY | - |
dc.subject.keywordPlus | SURVIVAL PREDICTION | - |
dc.subject.keywordPlus | SYMPTOM BURDEN | - |
dc.subject.keywordPlus | HYPOGONADISM | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | CACHEXIA | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.